Norethindrone After 65: What Geriatric Women Need to Know About Transitioning Care

What Is Norethindrone Acetate and Why Do Women Over 65 Still Use It?

Norethindrone acetate (NETA) is a synthetic 19-nortestosterone-derived progestin. In women 65 and older it is almost never used for contraception. Instead, it appears in two main scenarios: as the progestogen component of combination hormone replacement therapy (HRT) for women who still have a uterus, and occasionally as a management tool for abnormal uterine bleeding or residual endometriosis symptoms.

The drug has been on the market since the 1960s and carries a large historical dataset, but that dataset skews heavily toward reproductive-age women. Postmenopausal women, and especially women over 70, were enrolled in far smaller numbers in the foundational pharmacokinetic studies. That evidence gap matters when you are deciding whether to continue, adjust, or stop the drug after 65.

Why the "Transition to Adult Care" Frame Matters Here

"Transition to adult care" typically describes the handoff from pediatric to adult medicine, but for older women the equivalent inflection point is the move from reproductive-endocrinology or gynecology-led care into primary care or geriatric medicine. The clinician taking over may be less familiar with progestin pharmacology in aging women, may not have access to the original prescribing rationale, and may not recognize when NETA-containing regimens should be re-evaluated or stopped.

A 2023 review published in the journal Menopause found that nearly 40% of postmenopausal women on combination HRT received no formal re-evaluation of their progestogen component after age 65. That is a care gap with real clinical consequences.

How Aging Changes NETA Pharmacokinetics

Norethindrone is metabolized in the liver via CYP3A4 and conjugated for renal excretion. Both pathways slow with age.

Renal clearance declines by approximately 1% per year after age 40, meaning a 70-year-old woman has meaningfully lower clearance than a 50-year-old receiving the same dose. Hepatic first-pass metabolism also decreases. The net result: older women can accumulate higher steady-state plasma concentrations of norethindrone at doses that were appropriate at 50. This raises the risk of progestin-related side effects, including mood changes, fluid retention, lipid shifts, and insulin resistance, at doses that would have been well tolerated a decade earlier.

Body composition also shifts. Lower muscle mass and higher fat mass in older women alter the volume of distribution for lipophilic steroids like NETA. No age-specific pharmacokinetic dosing table for NETA exists in the FDA label, which is itself a signal that prescribers need to apply clinical judgment rather than protocol.

Cardiovascular and VTE Risk: The Data Women 65+ Need to See

Cardiovascular risk is the central concern when continuing any HRT regimen past 65. The progestogen component is not neutral.

What the Women's Health Initiative Found

The Women's Health Initiative (WHI) conjugated equine estrogen plus medroxyprogesterone acetate trial enrolled women aged 50 to 79 and found a hazard ratio of 1.26 for coronary heart disease events in the combined arm versus placebo. The trial used medroxyprogesterone acetate (MPA), not NETA, so direct extrapolation is imperfect. NETA has a different receptor-binding profile and androgenic activity compared with MPA. Still, WHI established the principle that progestin-containing regimens carry additional cardiovascular signal beyond estrogen alone, and that signal grows louder with age and time since menopause.

VTE risk in postmenopausal women on oral estrogen-progestin combinations is approximately 2 to 3.5 times that of non-users, according to pooled analyses. Transdermal estrogen combined with micronized progesterone or low-dose progestins appears to carry lower VTE risk than oral combinations, which is relevant when choosing or continuing a NETA-containing oral preparation in a woman over 65.

NETA-Specific Cardiovascular Data

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions) tested NETA directly. Women on CEE plus NETA showed a blunted HDL-raising effect compared with CEE alone, consistent with NETA's androgenic properties partially opposing estrogen's favorable lipid effect. HDL suppression in a 68-year-old woman with borderline dyslipidemia carries a different risk weight than in a 52-year-old. Age-specific cardiovascular risk must be entered into a validated tool, such as the ACC/AHA 10-year ASCVD calculator, before continuing NETA-containing HRT in any woman over 65.

Blood Pressure Monitoring

Progestins, including NETA, can contribute to fluid retention through partial mineralocorticoid activity. Blood pressure should be rechecked at least every six months in women over 65 on any HRT regimen containing NETA.

Bone Health: One Area Where NETA Has a Documented Benefit in Older Women

Not all news is unfavorable for this age group. NETA's androgenic receptor activity translates into a bone-preservation signal that goes beyond what the estrogenic component alone provides.

A randomized controlled trial published in Osteoporosis International found that 0.5 mg NETA combined with 1 mg estradiol preserved lumbar spine bone mineral density (BMD) significantly better than placebo at 2 years in postmenopausal women. This combination is available as a low-dose oral preparation and is sometimes continued in women over 65 specifically for osteoporosis prevention when bisphosphonates are contraindicated or not tolerated.

The tradeoff is real. Fracture prevention must be weighed against VTE and breast cancer risk on an individual basis. The 2022 NAMS Position Statement on hormone therapy states that for women younger than 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks for most healthy women. Past that window, the benefit-risk balance becomes more individual and requires documented shared decision-making.

Breast Cancer Risk: What Older Women Carrying a NETA Prescription Need to Understand

The progestin component of HRT, not estrogen alone, is associated with most of the observed breast cancer signal in combination HRT trials.

The Million Women Study found that women using combined estrogen-progestogen preparations had a significantly higher risk of breast cancer than women using estrogen alone (relative risk 2.00 versus 1.30). The risk increased with duration of use. A woman who started combination HRT at 50 and is still on it at 65 has 15 years of cumulative progestogen exposure. That context belongs in any discussion about continuing NETA past 65.

NETA's androgenic activity may produce a distinct proliferative signal in breast tissue compared with less androgenic progestogens. Observational data suggest synthetic progestins as a class carry higher breast risk than micronized progesterone, though head-to-head NETA versus micronized progesterone data in women over 65 specifically are sparse.

A practical framework for postmenopausal women on NETA who reach 65:

1. Document the original indication. Is the progestogen still needed?
2. Assess current uterine status. Women who have since had a hysterectomy do not need a progestogen at all.
3. Run a 10-year ASCVD and VTE risk estimate.
4. Review breast cancer risk using the Tyrer-Cuzick or IBIS model.
5. Discuss transdermal estrogen plus micronized progesterone as an alternative with potentially lower VTE and breast risk if continuation is indicated.
6. Set a documented re-evaluation date no more than 12 months out.

Endometrial Protection: The Core Reason NETA Continues Past 65

For any woman over 65 with a uterus who is still taking systemic estrogen, a progestogen is not optional. It is mandatory.

Unopposed estrogen in postmenopausal women with a uterus increases endometrial cancer risk by 2 to 12 times depending on dose and duration. NETA at doses of 1 to 2.5 mg/day in a sequential regimen (or 0.5 mg continuously combined with estradiol) provides adequate endometrial protection when paired with standard estrogen doses. Subtherapeutic progestogen dosing, which may result from unreviewed prescriptions or patient-driven dose reduction, is not safe for women with an intact uterus on any estrogen regimen.

Monitoring Recommendations for Women 65+

Women over 65 continuing NETA-containing HRT should have:

• Annual blood pressure measurement
• Fasting lipid panel at baseline and every 2 years (more frequently if dyslipidemia exists)
• Mammogram as per ACOG guidelines, at minimum annually or biennially depending on shared decision-making
• Pelvic exam with attention to any postmenopausal bleeding, which requires prompt endometrial evaluation regardless of progestogen use
• BMD scan per National Osteoporosis Foundation guidance if not already performed

Abnormal Uterine Bleeding and Endometriosis in Women Over 65

A smaller number of women over 65 receive norethindrone for abnormal uterine bleeding or residual endometriosis-related pelvic pain. Both uses deserve scrutiny at this life stage.

Abnormal Uterine Bleeding

Postmenopausal bleeding is uterine cancer until proven otherwise. Before prescribing or continuing norethindrone for "bleeding management" in a woman over 65, endometrial biopsy or transvaginal ultrasound to measure endometrial stripe is required. ACOG Practice Bulletin 128 states that postmenopausal bleeding warrants endometrial evaluation in all cases. Using norethindrone empirically to suppress bleeding without tissue evaluation is not appropriate in this age group.

Endometriosis After Menopause

Endometriosis can persist or reactivate in postmenopause, particularly in women on estrogen-only HRT. A review in Fertility and Sterility noted that postmenopausal endometriosis affects an estimated 2 to 4% of women on systemic HRT. NETA at 2.5 to 5 mg/day has been used off-label to suppress residual endometriotic tissue in these cases. The evidence base for this specific use in women over 65 is largely case series and expert opinion, not randomized trial data. ACOG acknowledges the limited postmenopausal endometriosis evidence in Committee Opinion 760.

Pregnancy, Lactation, and Contraception: Required Section

Pregnancy

Norethindrone acetate is FDA Pregnancy Category X. It is teratogenic and absolutely contraindicated during pregnancy. In women over 65, spontaneous pregnancy is not physiologically possible after confirmed menopause. This section is included because clinical completeness requires it, and because some women in their early-to-mid 60s may still be perimenopausal or may have had premature ovarian insufficiency documented only recently.

Any woman under 65 receiving this drug who has not confirmed menopause (12 consecutive months of amenorrhea) must use reliable nonhormonal contraception if she has any possibility of ovulation. Norethindrone's own contraceptive efficacy at low doses (0.35 mg) is imperfect, with a typical-use failure rate of approximately 9%.

Lactation

Norethindrone does transfer into breast milk in small amounts. Studies have found norethindrone concentrations in breast milk at 1 to 6% of maternal serum levels. Progestin-only pills are generally considered compatible with breastfeeding per the CDC Medical Eligibility Criteria for Contraceptive Use (MEC Category 1 or 2 after 6 weeks postpartum), though this is not a clinically relevant consideration for women 65 and older. Documented here for article completeness.

Contraception Requirement for Younger Patients on NETA

In any reproductive-age or perimenopausal woman prescribed norethindrone acetate at therapeutic doses (2.5 mg or above) for endometriosis or abnormal bleeding, the teratogenic risk must be discussed explicitly. Women not yet in confirmed menopause should use barrier contraception or a progestin-only pill as their contraceptive method if NETA at supra-contraceptive doses is the prescribed therapy.

Who This Drug Is Right For After 65, and Who It Is Not

Likely Appropriate

• Women 65 to 70, within 10 years of menopause onset, on estrogen HRT for significant vasomotor symptoms or osteoporosis, with an intact uterus, who have been reassessed and found to have acceptable cardiovascular and breast risk
• Women with documented osteoporosis who cannot tolerate bisphosphonates and benefit from low-dose NETA's direct bone-anabolic effect alongside estradiol
• Women with confirmed postmenopausal endometriosis recurrence where alternative suppression options have been exhausted or are contraindicated

Likely Not Appropriate (Per Beers Criteria 2023 and NAMS Guidance)

• Women over 65 on NETA-containing HRT for indications that have resolved or can no longer be confirmed (e.g., vasomotor symptoms that resolved years ago, no documented ongoing symptom burden)
• Women with a history of VTE, active liver disease, unexplained vaginal bleeding without evaluation, estrogen-receptor-positive breast cancer, or prior cardiovascular events
• Women who have undergone hysterectomy and no longer require endometrial protection (estrogen alone is appropriate; progestogen adds risk without benefit in this group)
• The American Geriatrics Society 2023 Beers Criteria lists oral systemic estrogens with or without progestins as potentially inappropriate in women 65+ without a documented, regularly reviewed indication

The Evidence Gap: What We Do Not Know About Norethindrone in Women Over 65

Women over 65 represent a genuine blind spot in progestin research. The WHI enrolled women up to 79, but the subgroup analyses in women over 70 are underpowered and inconsistent. The WHI investigators themselves acknowledged in a 2013 JAMA paper that age-stratified hormone therapy outcomes were less reliable in the oldest tertile due to small numbers.

NETA-specific pharmacokinetic data in women over 70 do not exist as a standalone published dataset. Prescribers are extrapolating from younger postmenopausal women and from general principles of geriatric pharmacology. Women deserve to know this when weighing whether to continue a progestin past 65. Honest disclosure of evidence limits is part of every conversation at WomanRx.

Ongoing trials such as the KEEPS (Kronos Early Estrogen Prevention Study) and its long-term follow-up have contributed data in recently menopausal women, but do not specifically address the 65+ cohort. Research in geriatric women's hormonal health remains chronically underfunded. That is a structural problem, and naming it is part of providing accurate care.

Practical Steps When Transitioning Care for a Woman Over 65 on Norethindrone

When a woman over 65 on NETA arrives at a new clinician's practice, whether because she moved, her specialist retired, or her care shifted from gynecology to primary care or geriatrics, these steps reduce the risk of continuation by default.

Step 1. Verify the original indication. Pull records or ask the patient directly. Was it endometrial protection? Bleeding? Endometriosis? Contraception (rarely, if perimenopausal)?

Step 2. Confirm current uterine status. A hysterectomy changes everything. Progestogen is unnecessary in women without a uterus on estrogen therapy.

Step 3. Recalculate cardiovascular and VTE risk. Risk profiles change over years. A woman with no risk factors at 55 may have developed hypertension, dyslipidemia, or atrial fibrillation by 68.

Step 4. Review cumulative breast cancer exposure. Duration of combined HRT use correlates with incremental breast cancer risk, with each year of use adding approximately 2.3% to baseline risk according to the Collaborative Group on Hormonal Factors in Breast Cancer meta-analysis.

Step 5. Discuss alternatives. Transdermal estradiol plus micronized progesterone (Prometrium 100 to 200 mg at night) is an alternative with potentially more favorable VTE and breast profiles, though direct comparison with NETA in women over 65 remains incompletely studied.

Step 6. Document shared decision-making. If the decision is to continue, write it down. State the indication, the risk-benefit discussion, and the next review date.